NTLA
Price
$23.61
Change
+$1.08 (+4.80%)
Updated
Sep 19, 10:39 AM (EDT)
42 days until earnings call
PTGX
Price
$46.34
Change
+$1.58 (+3.53%)
Updated
Sep 19, 10:45 AM (EDT)
48 days until earnings call
Ad is loading...

NTLA vs PTGX

Header iconNTLA vs PTGX Comparison
Open Charts NTLA vs PTGXBanner chart's image
Intellia Therapeutics
Price$23.61
Change+$1.08 (+4.80%)
Volume$700
CapitalizationN/A
Protagonist Therapeutics
Price$46.34
Change+$1.58 (+3.53%)
Volume$813
CapitalizationN/A
View a ticker or compare two or three
NTLA vs PTGX Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
NTLA vs. PTGX commentary
Sep 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Buy and PTGX is a Hold.

COMPARISON
Comparison
Sep 19, 2024
Stock price -- (NTLA: $22.52 vs. PTGX: $44.77)
Brand notoriety: NTLA and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 131% vs. PTGX: 84%
Market capitalization -- NTLA: $2.29B vs. PTGX: $2.65B
NTLA [@Biotechnology] is valued at $2.29B. PTGX’s [@Biotechnology] market capitalization is $2.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $599.73B to $0. The average market capitalization across the [@Biotechnology] industry is $3.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 0 FA rating(s) are green whilePTGX’s FA Score has 2 green FA rating(s).

  • NTLA’s FA Score: 0 green, 5 red.
  • PTGX’s FA Score: 2 green, 3 red.
According to our system of comparison, PTGX is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while PTGX’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 3 bearish.
  • PTGX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than PTGX.

Price Growth

NTLA (@Biotechnology) experienced а +11.26% price change this week, while PTGX (@Biotechnology) price change was -0.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.81%. For the same industry, the average monthly price growth was +7.77%, and the average quarterly price growth was +2.01%.

Reported Earning Dates

NTLA is expected to report earnings on Oct 31, 2024.

PTGX is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (+7.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($2.65B) has a higher market cap than NTLA($2.29B). PTGX YTD gains are higher at: 95.246 vs. NTLA (-26.140). PTGX has higher annual earnings (EBITDA): 156M vs. NTLA (-514.18M). NTLA has more cash in the bank: 691M vs. PTGX (564M). PTGX has less debt than NTLA: PTGX (11M) vs NTLA (106M). PTGX has higher revenues than NTLA: PTGX (319M) vs NTLA (46M).
NTLAPTGXNTLA / PTGX
Capitalization2.29B2.65B87%
EBITDA-514.18M156M-330%
Gain YTD-26.14095.246-27%
P/E RatioN/A16.46-
Revenue46M319M14%
Total Cash691M564M123%
Total Debt106M11M964%
FUNDAMENTALS RATINGS
NTLA vs PTGX: Fundamental Ratings
NTLA
PTGX
OUTLOOK RATING
1..100
1015
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
9243
SMR RATING
1..100
9622
PRICE GROWTH RATING
1..100
7736
P/E GROWTH RATING
1..100
10022
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (44) in the Biotechnology industry is in the same range as PTGX (67). This means that NTLA’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (43) in the Biotechnology industry is somewhat better than the same rating for NTLA (92). This means that PTGX’s stock grew somewhat faster than NTLA’s over the last 12 months.

PTGX's SMR Rating (22) in the Biotechnology industry is significantly better than the same rating for NTLA (96). This means that PTGX’s stock grew significantly faster than NTLA’s over the last 12 months.

PTGX's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for NTLA (77). This means that PTGX’s stock grew somewhat faster than NTLA’s over the last 12 months.

PTGX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for NTLA (100). This means that PTGX’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAPTGX
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 14 days ago
85%
Bearish Trend 1 day ago
76%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BIEEX16.34N/A
N/A
BlackRock GA Dynamic Eq Instl
RSERX20.28N/A
N/A
Victory Sophus Emerging Markets R6
GCTCX41.27N/A
N/A
Goldman Sachs US Tax-Managed Eq C
SNOAX33.41N/A
N/A
Easterly Snow Long/Short Opportunity A
FMMMX43.56-0.10
-0.23%
American Funds AMCAP 529-F-2

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with BEAM. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-0.13%
BEAM - NTLA
75%
Closely correlated
-0.27%
EDIT - NTLA
74%
Closely correlated
+0.26%
CRSP - NTLA
71%
Closely correlated
-0.64%
VCYT - NTLA
69%
Closely correlated
-1.63%
PRME - NTLA
68%
Closely correlated
-0.50%
More

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with RCKT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
-0.31%
RCKT - PTGX
46%
Loosely correlated
-4.40%
NTLA - PTGX
45%
Loosely correlated
-0.13%
VIR - PTGX
44%
Loosely correlated
-1.51%
RCUS - PTGX
43%
Loosely correlated
-1.43%
BEAM - PTGX
41%
Loosely correlated
-0.27%
More